The combination of an oncolytic virus known as talimogene laherparepvec with ipilimumab yielded a significantly higher response rate than ipilimumab alone in a phase II study of patients with advanced melanoma.
Archive | MRV Research
Oncolytic Virus Plus Ipilimumab Improves Responses in Advanced Melanoma
Posted in Melanoma News, MRV Research, MRV Projects
National Skin Cancer Action Week 19-25 November 2018
Ahead of this year’s National Skin Cancer Action Week, MMP clinicians and researchers descended on Brisbane for a joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research – the world’s largest congress on melanoma with over 1500 delegates from 53 countries.
Posted in Melanoma News, MRV Projects
Vote for Jessica Duarte, one of MMP’s awesome young scientists.
Summary of her project: Melanoma, known as Australia’s national cancer, is the deadliest type of skin cancer with the highest rates being reported in Australia and New Zealand (~60 cases per 100 000 individuals per year). Locally, melanoma is also the most commonly diagnosed cancer in young Australians aged between 15 and 39 years, making […]
Posted in Melanoma News, MRV Projects
Investigating Lentigo Maligna
Lentigo maliga is a type of in-situ (superficial) melanoma which often presents a treatment challenge as it commonly occurs on cosmetically sensitive areas of the head and neck of elderly patients and may require several surgical procedures to achieve adequate clearance.
Posted in MRV Projects
